The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the ...

Reduced Weight Regain: CCT-217 shows promise in preventing weight regain commonly observed after discontinuing incretin ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the ...

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...

The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

Venture capital firms incubate, grow and finance dozens of drug companies each year. Follow the money they channel into the ...

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...